Shares of Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is GBX 2,325 ($31.13).
Several equities research analysts have recently commented on the company. Berenberg Bank raised Hikma Pharmaceuticals to a “buy” rating and boosted their price target for the stock from GBX 2,100 ($28.12) to GBX 2,400 ($32.14) in a research note on Monday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($36.82) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th.
View Our Latest Research Report on HIK
Hikma Pharmaceuticals Trading Up 0.3 %
Hikma Pharmaceuticals Cuts Dividend
The firm also recently declared a dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, August 15th were issued a $0.32 dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend was Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is 9,538.46%.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Should You Invest in Treasury Bills?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.